Proteintech reaches 500,000 product citations
Proteintech products have now been cited in more than 500,000 peer-reviewed publications worldwide.
What does 500,000 look like in perspective?
To put this milestone into context, imagine 500,000 sheets of paper laid end to end. The resulting distance would be enough to reach the edge of space or scale Mount Everest more than 15 times.*
The physical scale is impressive, but 500,000 is more than just a number. It’s 500,000 times researchers trusted Proteintech products for their research. Behind those citations are real scientists who have spent countless hours in the lab, making ground-breaking discoveries, and advancing scientific knowledge across virtually every area of life science.
What does 500,000 citations mean for researchers?
For researchers, confidence in an antibody means greater confidence in the data it generates. With more than 500,000 citations, Proteintech antibodies have supported research across a wide range of scientific fields. But behind every reliable result is the need for reagents that perform consistently, with transparent evidence of their specificity and suitability for the intended application.
Building trust through original manufacturing and validation.
Choosing antibodies from an original manufacturer gives researchers greater transparency into how their reagents are developed, produced, and validated.
Since 2001, Proteintech has developed and manufactured its own primary antibodies against more than 14,000 targets. This direct oversight supports consistent quality across production lots and provides researchers with greater insight into the products they use, helping them make informed decisions and address the challenges of scientific reproducibility.
Target-specific validation helps researchers make informed choices. Proteintech's approach combines using physiologically relevant models, appropriate genetic controls, and complementary antibody-dependent and orthogonal methods to evaluate antibody specificity and performance across multiple applications. Also, as technologies continue to evolve so has our approach to validation. Techniques such as epitope mapping provide additional insight into antibody-target interactions at the amino acid level, helping researchers better understand binding specificity and predict potential cross-reactivity.
Transparent validation data supports reproducibility
Access to original validation evidence helps researchers independently assess whether an antibody is suitable for their experiments. Unaltered validation data, including whole-slide immunohistochemistry (IHC) images and original raw data upon request, provides greater visibility into antibody performance.
For more information, read our Antibody Validation Policy.
Reliable support helps researchers move forward with confidence
Through our product guarantee, researchers have access to PhD-level technical support or options for a replacement, exchange, or refund of the product. Our dedicated technical support team can also work with researchers and the scientists behind our products to troubleshoot challenges and help optimize workflows.
This commitment to being in control of the product lifecycle, from development through its use in the lab, reflects the vision that CEO, Dr. Jason Li had when he founded Proteintech 25 years ago.
500,000 and counting
Over the past 25 years, Proteintech’s portfolio has grown alongside the evolving needs of the scientific community and now includes antibodies for 14,000+ targets, alongside an expanding range of recombinant products, kits, and Nanobody based reagents.
As we celebrate this milestone, we want to thank all the researchers around the world who have trusted Proteintech as part of their work. We are excited to continue supporting the industry with the next 500,000 publications!
*Based on 500,000 A4 sheets placed end to end (long edge). Figures are approximate and for illustration only.
Able™